PIIb DMD trial approved in Bulgaria- UK, Australia advancing
Filed with ASX · · 2 pages · English
Percheron Therapeutics Limited on 6ix
Earlier from Percheron Therapeutics
- Dosing commenced in the ATL1102 toxicology study
- Receipt of R&D Tax Incentive Payment
- First approval for ATL1102 Phase IIb DMD clinical trial
- Limb Girdle Muscular Dystrophy R2 animal study commenced
- Positive outcomes in DMD combination therapy animal study
Later from Percheron Therapeutics
- Chief Executive Officer and Managing Director Appointment
- First Patient Dosed in ATL1102 Phase IIb DMD Trial
- MHRA approval for ATL1102 Phase IIb DMD clinical trial in UK
- Institutional Placement and proposed Share Purchase Plan SPP
- Quarterly Activities Report
Follow Percheron Therapeutics into a list and get an email when it puts out news.
Follow Percheron Therapeutics